SecBot SecBot
8-K ·Filed May 4, 2026

ORIC

Oric Pharmaceuticals, Inc.
MIXED
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-203993
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The earnings miss may pressure the stock near-term, but positive clinical data and strong cash runway support the pipeline narrative. Watch for initiation of the Himalayas-1 Phase 3 trial in 1H 2026 and multiple data readouts in 2H 2026.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.57
T+0 close · May 4, 2026 · via day close
Latest settled
+21.63%
T+60 · $11.64
Vs SPY
+18.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $9.57entry
  2. T+1 · 7mo ago 0.00%α −1.38% · $9.57
  3. T+5 · 6mo ago −6.06%α −8.04% · $8.99
  4. T+20 · 6mo ago −20.38%α −25.33% · $7.62
  5. T+60 · 4mo ago +21.63%α +18.89% · $11.64
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9.7%, as R&D spending increased to $31.4M. However, the company announced selection of rinzimetostat RP3D and positive clinical data, with cash of $419.7M funding operations into 2H 2028.

Key Financial Metrics

EPS
−$0.34
est −$0.31 · -9.7%
Rating
miss

Key Facts

  • Net loss per share $(0.34) vs consensus $(0.31) (EPS miss of ~9.7%)
  • Q1 2026 net loss $35.8M vs $30.0M in Q1 2025, driven by higher R&D costs
  • Cash, cash equivalents and investments $419.7M as of March 31, 2026
  • R&D expenses $31.4M, up 27.5% YoY due to advancement of rinzimetostat and enozertinib
  • Selected rinzimetostat 400 mg once daily as RP3D for Himalayas-1 Phase 3 trial in post-abiraterone mCRPC
  • Positive rinzimetostat data showing landmark rPFS rates superior to standard of care
  • Initiation of first Phase 3 registrational trial expected in 1H 2026

Financial Impact

EPS miss of $0.03 (9.7%) vs consensus; higher net loss due to increased R&D spending

net lossepscash

Risk Factors

  • EPS miss and higher net loss could disappoint short-term traders
  • Clinical trial risks, including potential delays or negative data
  • Dilution risk from continued ATM offerings (raised $59.9M in Q1 2026)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-203993
Document: oric-20260504.htm0001193125-26-203993
Document: 0001193125-26-203993-index-headers.html0001193125-26-203993
Document: 0001193125-26-203993-index.html0001193125-26-203993
Document: 0001193125-26-203993.txt0001193125-26-203993
8-K Data (Synthetic)0001193125-26-203993

Track record

12 reports on ORIC

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Press Release Neutral 5/10 Entry $7.52 Now $7.52 −0.00% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $7.59 Now $7.52 −0.92% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.72 Now $7.52 −2.59% settles Nov 23
  4. Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $8.91 Now $7.52 −15.60% settles Nov 17
  5. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $13.17 to $9.24 Now $7.52 −42.90% ▼ −29.84% −29.28% vs SPY
  6. Oct 5, 20266w ago Press Release Bullish 6/10 Entry $11.98 to $11.31 Now $7.52 −37.23% ▼ −5.59% −5.45% vs SPY
  7. Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $12.49 to $11.81 Now $7.52 −39.79% ▼ −5.44% −5.87% vs SPY
  8. Aug 3, 202615w ago Press Release Neutral 5/10 Entry $13.47 to $13.73 Now $7.52 −44.17% ▲ +1.93% +2.03% vs SPY
  9. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.91 to $10.16 Now $7.52 −15.60% ▲ +13.97% +12.96% vs SPY
  10. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $7.82 to $8.63 Now $7.52 −3.84% ▲ +10.36% +9.92% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026